Greenwich LifeSciences, Inc. (NASDAQ:GLSI) Short Interest Update

Greenwich LifeSciences, Inc. (NASDAQ:GLSI) saw a large increase in short interest during the month of January. As of January 31st, there was short interest totalling 644,000 shares, an increase of 5.1% from the January 15th total of 612,700 shares. Currently, 10.9% of the company’s shares are short sold. Based on an average daily volume of 33,700 shares, the short-interest ratio is presently 19.1 days.

Greenwich LifeSciences Price Performance

NASDAQ:GLSI opened at $12.51 on Wednesday. The business has a 50 day moving average price of $12.56 and a 200-day moving average price of $13.43. Greenwich LifeSciences has a fifty-two week low of $10.52 and a fifty-two week high of $21.44.

Insider Activity at Greenwich LifeSciences

In other Greenwich LifeSciences news, CEO Snehal Patel purchased 2,500 shares of the business’s stock in a transaction on Friday, January 10th. The stock was acquired at an average cost of $12.51 per share, for a total transaction of $31,275.00. Following the completion of the transaction, the chief executive officer now directly owns 5,552,502 shares in the company, valued at approximately $69,461,800.02. This represents a 0.05 % increase in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. In the last 90 days, insiders have acquired 10,500 shares of company stock valued at $128,459. Insiders own 51.67% of the company’s stock.

Institutional Investors Weigh In On Greenwich LifeSciences

Large investors have recently added to or reduced their stakes in the company. Geode Capital Management LLC raised its stake in shares of Greenwich LifeSciences by 4.6% during the third quarter. Geode Capital Management LLC now owns 133,550 shares of the company’s stock valued at $1,919,000 after acquiring an additional 5,861 shares during the last quarter. Northern Trust Corp raised its position in Greenwich LifeSciences by 17.3% during the 4th quarter. Northern Trust Corp now owns 87,423 shares of the company’s stock valued at $982,000 after purchasing an additional 12,923 shares during the last quarter. State Street Corp lifted its holdings in Greenwich LifeSciences by 4.4% in the 3rd quarter. State Street Corp now owns 71,408 shares of the company’s stock worth $1,026,000 after buying an additional 3,005 shares during the period. Garden State Investment Advisory Services LLC purchased a new position in shares of Greenwich LifeSciences during the third quarter valued at approximately $253,000. Finally, Barclays PLC increased its stake in shares of Greenwich LifeSciences by 12.7% during the fourth quarter. Barclays PLC now owns 9,648 shares of the company’s stock valued at $108,000 after buying an additional 1,088 shares during the period. Institutional investors own 4.16% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reissued a “buy” rating and issued a $38.00 target price on shares of Greenwich LifeSciences in a research note on Tuesday, February 11th.

About Greenwich LifeSciences

Greenwich LifeSciences, Inc, a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery.